Introduction
When research on luteinizing hormone-releasing hormone (LH-RH) and analogues started in many pharmaceutical companies, it was predicted that these agents would be used for the treatment of hypogonadal states in human clinical medicine and for the regulation and improvement of fertility in veterinary medicine. The major objective, however, was to produce an antagonist of LH-RH which could be used primarily as an antifertility agent in men and women. Like a number of other biologically potent molecules the unexpected results provided by LH-RH and its agonistic analogues changed both the impetus and direction of research.
The finding that potent analogues of LH-RH would prevent puberty when given continuously to immature female rats and would cause ovarian and uterine atrophy in mature rats (Johnson, Gendrich & White, 1976; Vale, Rivier, Rivier & Brown, 1977 ) prompted a rapid re-appraisal of the therapeutic potential of these agents. The paradoxical anti-gonadal effect was not confined to the female since potent analogues of LH-RH were shown to prevent sexual maturation in the male, to reduce the weights of the testes and accessory sex organs, and to arrest spermatogenesis and decrease plasma androgens (Oshima et al, 1975; Auclair, Kelly, Labrie, Coy & Schally, 1977; Vale et al, 1977; Pelletier et al, 1978; Tcholakian et al, 1978; Rivier, Riviera Vale, 1979) .
Although prevention of conception remains a very important potential use for potent LH-RH analogues, a number of problems will have to be overcome before such agents reach the stage of extensive clinical trial. In the shorter term exploitation of the castration-like effects produced by LH-RH analogues will be in the treatment of precocious puberty, endometriosis and benign and malignant diseases of the breast and prostate. Since clinical trials are now beginning with these agents in the treatment of hormone-responsive tumours, it is timely to describe data from tumour models in animals which support the belief that analogues of LH-RH may well prove clinically effective.
Rat mammary tumours induced by dimethylbenzanthracene (DMBA) Huggins, Grand & Brillantes (1961) showed that administration of DMBA to young female rats resulted in the formation of mammary tumours. This so-called DMBA-induced mammary tumour model has proved most valuable for the study of hormone-dependent cancer because it responds to a range of ablative and additive endocrine therapies that are effective in women with Arbogast, 1974; Nicholson & Golder, 1975; Jordan, 1976; Jordan & Koerner, 1976; Manni et al, 1977) , progesterone (Huggins et al, 1961) and cytotoxic agents (Fiebig & Schmahl, 1977) all produce tumour regression. The observations of Danguy et al. (1977) and Desombre, Johnson & White (1978) (Dutta, Furr, Giles & Valcaccia, 1978a) .
In all studies the tumours were measured by calipers along the longest axis and the axis perpendicular to it. In an initial experiment (Dutta, Furr, Giles, Valcaccia & Walpole, 1978b) (Table 3 ) and caused the appearance of a persistent pattern of dioestrous vaginal smears (Nicholson, Walker & Maynard, 1980 primates (Belchetz, Plant, Nakai, Keogh & Knobil, 1978) and man (Berquist, Nillius & Wide, 1979) , and consequently prevents gonadal stimulation. However, the dosing regimen used in the dose-response study described here did not prevent LH release in the rat . Text- figure 6 shows that, although reduced, sustained LH (Hsueh, Dufau & Catt, 1976 Sharpe, 1976; Auclair et al, 1977) . Moreover, a similar down-regulation of gonadal LH receptors is observed after administration of LH-RH analogues (Auclair et al, 1977; Conti, Harwood, Dufau & Catt, 1977; Kledzik, Cusan, Auclair, Kelly & Labrie, 1978; Catt, Bakaul, Davies & Dufau, 1979 ). Once again, however, it is unlikely that this represents the complete mechanism of ICI 118630 action since the concurrent administration of the drug with hCG to hypophysectomized rats completely abolishes the hCG-stimulated increases in ovarian and uterine weights (Table 5) Table 6 . This was probably a consequence of the reduction in plasma oestradiol, because oestrogens regulate prolactin release in the rat (Meites, 1972; Jordan & Koerner, 1976) . The interaction of oestrogen and prolactin in controlling growth of DMBA-induced tumours is worthy of further study before firm conclusions can be drawn about the relative importance of oestrogen and prolactin withdrawal on tumour growth. 
